Terms: = Thyroid cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2 AND Diagnosis
94 results:
1. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
2. Papillary thyroid carcinoma tall cell subtype (PTC-TC) and high-grade differentiated thyroid carcinoma tall cell phenotype (HGDTC-TC) have different clinical behaviour: a retrospective study of 1456 patients.
Ghossein R; Katabi N; Dogan S; Shaha AR; Tuttle RM; Fagin JA; Ganly I; Xu B
Histopathology; 2024 Jun; 84(7):1130-1138. PubMed ID: 38528726
[TBL] [Abstract] [Full Text] [Related]
3. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
4. A Misleading Case of NTRK-Rearranged Papillary thyroid Carcinoma.
Germani MM; Boccaccio C; Matrone A; Molinaro E; Alì G; Giordano M; Elisei R; Fontanini G; Cremolini C
Oncologist; 2024 Jan; 29(1):84-88. PubMed ID: 38037189
[TBL] [Abstract] [Full Text] [Related]
5. Age-associated mortality is partially mediated by tert promoter mutation status in differentiated thyroid carcinoma.
Heo J; Lee S; Park J; Yang H; Park H; Ki CS; Oh YL; Kim HI; Kim SW; Chung JH; Kim K; Kim TH
PLoS One; 2023; 18(11):e0294145. PubMed ID: 37948420
[TBL] [Abstract] [Full Text] [Related]
6. Genetic alterations landscape in paediatric thyroid tumours and/or differentiated thyroid cancer: Systematic review.
de Sousa MSA; Nunes IN; Christiano YP; Sisdelli L; Cerutti JM
Rev Endocr Metab Disord; 2024 Feb; 25(1):35-51. PubMed ID: 37874477
[TBL] [Abstract] [Full Text] [Related]
7. Performance of multigene testing in cytologically indeterminate thyroid nodules and molecular risk stratification.
Zhou Y; Wu X; Zhang Y; Li Z; Ge X; Chen H; Mao Y; Ding W
PeerJ; 2023; 11():e16054. PubMed ID: 37744220
[TBL] [Abstract] [Full Text] [Related]
8. DICER1 Mutations Do Not Always Indicate Dismal Prognosis in Pediatric Poorly Differentiated thyroid Carcinomas.
Yegen G; Altay AY; Yılmaz İ; İşcan Y; Sormaz İC; Aksakal N; Önder S; Mete Ö
Endocr Pathol; 2023 Sep; 34(3):279-286. PubMed ID: 37574466
[TBL] [Abstract] [Full Text] [Related]
9. Incidence and Clinicopathological Features of Differentiated High-Grade thyroid Carcinomas: An Institutional Experience.
Jeong SI; Kim W; Yu HW; Choi JY; Ahn CH; Moon JH; Choi SI; Cha W; Jeong WJ; Park SY; Na HY
Endocr Pathol; 2023 Sep; 34(3):287-297. PubMed ID: 37515661
[TBL] [Abstract] [Full Text] [Related]
10. Facilitation of Definitive cancer diagnosis With Quantitative Molecular Assays of BRAF V600E and tert Promoter Variants in Patients With thyroid Nodules.
Fu G; Chazen RS; Monteiro E; Vescan A; Freeman JL; Witterick IJ; MacMillan C
JAMA Netw Open; 2023 Jul; 6(7):e2323500. PubMed ID: 37505499
[TBL] [Abstract] [Full Text] [Related]
11. Mutational profiling of Chinese patients with thyroid cancer.
Du Y; Zhang S; Zhang G; Hu J; Zhao L; Xiong Y; Shen L; Chen R; Ye K; Xu Y
Front Endocrinol (Lausanne); 2023; 14():1156999. PubMed ID: 37465126
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary thyroid cancer.
Schumm MA; Shu ML; Hughes EG; Nikiforov YE; Nikiforova MN; Wald AI; Lechner MG; Tseng CH; Sajed DP; Wu JX; Yeh MW; Livhits MJ
JAMA Otolaryngol Head Neck Surg; 2023 Aug; 149(8):735-742. PubMed ID: 37382944
[TBL] [Abstract] [Full Text] [Related]
13. Genetic Considerations in the Tumorigenesis, diagnosis, and Treatment of Differentiated thyroid cancer: Current State of the Science.
Richmond BK; Gallimore J
Am Surg; 2023 Nov; 89(11):4853-4859. PubMed ID: 37253623
[TBL] [Abstract] [Full Text] [Related]
14. [Clinical significance of multigene assay in papillary thyroid carcinoma].
Shi Y; Qian K; Guo K; Liu J; Wang Z
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 May; 37(5):375-379. PubMed ID: 37138401
[No Abstract] [Full Text] [Related]
15. Papillary thyroid Carcinomas with Tall Cell Features: An Intermediate Entity Between Classic and Tall Cell Subtypes.
Bikas A; Wong K; Pappa T; Ahmadi S; Wakefield CB; Marqusee E; Xiang P; Altshuler B; Haase J; Barletta JA; Landa I; Alexander EK
Thyroid; 2023 Jun; 33(6):697-704. PubMed ID: 36960703
[No Abstract] [Full Text] [Related]
16. Brain metastases of papillary thyroid carcinoma origin are derived from aggressive histologic variants and demonstrate similar adverse morphology in the metastatic lesion.
Gubbiotti MA; Livolsi V
Clin Neurol Neurosurg; 2023 Apr; 227():107639. PubMed ID: 36889238
[TBL] [Abstract] [Full Text] [Related]
17. Real-life utility of five-gene panel test in preoperative thyroid fine-needle aspiration biopsy: a large cohort of 740 patients study.
Tang J; Ma J; Xi X; Wang L; Li H; Huo S; Zhang B
Endocrine; 2023 Jun; 80(3):552-562. PubMed ID: 36542267
[TBL] [Abstract] [Full Text] [Related]
18. [Diagnostic values of cyclin D1 immunocytochemistry and molecular testing in preoperative fine needle aspiration of undeterminate thyroid nodules].
He SR; Zhang JX; Chen RM; Hu ST; Yang L; Chen L; Zhang Z; Liu DG
Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1210-1216. PubMed ID: 36480828
[No Abstract] [Full Text] [Related]
19. Molecular testing in fine-needle aspiration of thyroid nodules.
McMurtry V; Canberk S; Deftereos G
Diagn Cytopathol; 2023 Jan; 51(1):36-50. PubMed ID: 36480743
[TBL] [Abstract] [Full Text] [Related]
20. thyroid carcinoma metastases to central nervous system and vertebrae.
Kleinschmidt-DeMasters B; Marshall C
Folia Neuropathol; 2022; 60(3):292-300. PubMed ID: 36382481
[TBL] [Abstract] [Full Text] [Related]
[Next]
